Fusidic Acid
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Fusidic Acid: From Staphylococcal Infection to Exposure Keratitis
One-Sentence Summary
Fusidic acid is a long-established antistaphylococcal antibiotic, traditionally used for skin, soft-tissue and ocular bacterial infections, though the specific original indication and marketing authorisation details are not recorded in this evidence pack. The TxGNN model’s top prediction is exposure keratitis, but this is currently supported by only 1 case-series publication and no clinical trials, making it a very early-stage, low-confidence signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (data gap); fusidic acid is generally established as an antistaphylococcal antibiotic for skin, soft-tissue and ocular infections |
| Predicted New Indication | Exposure keratitis |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for fusidic acid in this pack (data gap). Based on generally established pharmacology, fusidic acid is a steroid-like antibiotic that inhibits bacterial protein synthesis by blocking elongation factor G (EF-G), with activity concentrated against Gram-positive organisms, particularly Staphylococcus aureus (including MRSA/MRSP).
Exposure keratitis itself is a mechanical/non-infectious condition caused by inadequate eyelid closure, so fusidic acid has no direct effect on the primary pathology. Its relevance is limited to prevention or treatment of secondary bacterial infection of the exposed corneal surface — ophthalmic fusidic acid formulations (e.g. Fucithalmic) are already used for bacterial conjunctivitis/keratitis in some markets. This is an indirect, adjunctive mechanistic link rather than a primary therapeutic hypothesis, which is reflected in the single supporting case series (relevance not yet graded).
Notably, other TxGNN-ranked candidates for this drug show stronger and more mechanistically direct evidence — otitis externa (L3, six literature sources on staphylococcal/coryneform ear infections) and post-bacterial disorder (L2, including a completed Phase 3 RCT of oral sodium fusidate in acute bacterial skin and skin-structure infections, NCT02570490). These reinforce the biological plausibility of fusidic acid repurposing within its known antistaphylococcal spectrum, even though the top-ranked exposure keratitis signal remains weak on its own.
Clinical Trial Evidence
Currently no related clinical trials registered for exposure keratitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31246677 | 2019 | Case series | Cornea | Largest reported case series of Tsukamurella-associated ophthalmic infections, including a case of ocular implant infection after enucleation; relevance to exposure keratitis not yet graded |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: MHRA product-specific warnings, contraindications and drug interaction data could not be retrieved for this evidence pack (blocking data gap, DG001) and must be obtained before any safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (exposure keratitis) rests on a single, non-graded case series with only an indirect mechanistic rationale (secondary infection prophylaxis, not treatment of the primary mechanical pathology), and no clinical trials exist for this specific indication. Compounding this, MHRA-level safety data (warnings/contraindications) is an unresolved blocking gap, and the drug currently holds no UK marketing authorisation.
To proceed, the following is needed:
- MHRA SmPC warnings and contraindications (resolves blocking gap DG001)
- Confirmed mechanism of action via DrugBank (resolves DG002)
- Dedicated clinical evidence (case-control or trial data) specifically evaluating fusidic acid in exposure keratitis, given only one pending-relevance case series currently exists
- Consideration of re-prioritising evaluation toward otitis externa (L3) or post-bacterial disorder (L2, completed Phase 3 RCT) as more evidence-backed repurposing candidates for this drug
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.